Prognostic Models From Transcriptomic Signatures of the Tumor Microenvironment and Cell Cycle in Stage III Colon Cancer From PETACC-8 and IDEA-France Trials Individual patient data of neoadjuvant RCTs ...
There has been another twist in the road for the ongoing legal battle between Seagen and Daiichi Sankyo over patent rights for antibody-drug conjugate (ADC) Enhertu. The US Patent and Trademark ...
A US jury has decided that Daiichi Sankyo and AstraZeneca's breast cancer drug Enhertu infringes a patent held by US biotech Seagen, awarding almost $42 million in damages. Seagen claims Enhertu ( ...
Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. | ...
Fields is now on a drug approved by the Food and Drug Administration named Enhertu, developed and commercialized by biotech giants AstraZeneca and Daiichi Sankyo ... from Seagen in 2019, was ...
The Micro Immune Response On chip (MIRO) allows tumours and their environment to be replicated in order to understand their response to immunotherapy-based treatments. The device, which has already ...
Seagen, Inc., Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., AstraZeneca, and Daiichi Sankyo are developing and marketing these medications. For instance, in October 2018 ...
Chen reports serving as a consultant for AstraZeneca, Daiichi Sankyo, Guardant Health, Novartis, Seagen and Stemline. Please see the study for all other researchers’ relevant financial disclosures.
Background: Derived neutrophil-to-lymphocyte ratio (dNLR) is a biomarker associated with clinical outcome in breast cancer (BC). We analyzed the association of dNLR with pathological complete response ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback